Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:52 PM
Ignite Modification Date: 2025-12-24 @ 7:52 PM
NCT ID: NCT00677404
Eligibility Criteria: Inclusion Criteria: * Presence of Critical Limb ischemia according to the guidelines of the Transatlantic Consensus Group (TASC) Rutherford grade II or III. Perfusion is measured with absolute perfusion pressure and ankle-brachial index (ABI) and transcutaneous oxygen tension (TcpO2); for inclusion, ABI has to be less than or equal to 0.6 or absolute ankle pressure must be less than 60 mmHg. If ABI is technically not feasible, e.g. in patients with media calcification, inclusion criteria are a tcpO2 value (supine, forefoot, 44°C) of less than 20 mmHg if there is no tissue loss, or a tcpO2 of less than 40 mmHg if there is tissue loss. * No sufficient response to best standard care delivered for six weeks. * No surgical or radiological interventional option for revascularisation as confirmed by a vascular surgeon and an interventional radiologist * Signed informed consent * Absence of life-threatening complications from the ischemic limb Exclusion Criteria: * Expected life span less than six months * Bone marrow diseases which preclude transplantation (eg lymphoma, leukaemia, myelodysplastic syndrome and others) * Patients with poorly controlled diabetes mellitus (HbA1C \> 8%) * Patients with renal insufficiency (creatinine \> 2.5). * Patients with evidence of infectious disease as determined by e. above or other medical findings. * Pregnant women (women capable of childbearing must have a negative pregnancy test). * Patients with cognitive impairments. * Other comorbid disease that would be expected to result in less than one year life expectancy * Past malignancy or history of chemotherapy or radiation affecting the bone marrow. * History of inflammatory or progressively fibrotic conditions: .e.g., rheumatoid arthritis, systemic lupus erythematosis, vasculitic disorders, idiopathic pulmonary fibrosis, retroperitoneal fibrosis * Infection as evidenced by WBC count of \>15,000 and/or temperature more than 38C. Large area of cellulitis in the afflicted limb that in the opinion ofthe investigators would require the institution of antibiotics OR evidence of osteomyelitis corroborated by radiographic or scintigraphic examination * Cardiovascular conditions: * EF\<30% * Acute ST elevation myocardial infarction (MI) within 1month; * Transient ischemic attack or stroke within 1 month; * Severe valvular disease * CVA * Patients with any history of organ transplants
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00677404
Study Brief:
Protocol Section: NCT00677404